Table of Content

1. Introduction To Targeted Alpha Therapy
1.1 Overview
1.2 Alpha Radiation vs. Beta & Gamma Radiation In Cancer Therapy


2. Targeted Alpha Therapy - Structure & Mechanism Of Action
2.1 Structure
2.2 Mechanism Of Action


3. Targeted Alpha Therapy Applications By Cancer
3.1 Hematological Malignancies
3.2 Solid Tumors


4. Global Targeted Alpha Therapy Market Insight
4.1 Current Market Scenario
4.2 Future Growth Avenues


5. Targeted Alpha Therapy Market Insight By Region
5.1 US
5.2 Europe
5.3 China
5.4 Japan
5.5 Australia


6. Targeted Alpha Therapy Clinical Trials Insight By Company, Country, Indication & Phase
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
6.7 Phase III


7. Marketed Targeted Alpha Therapy Clinical Insight By Company, Country & Indication


8. Xofigo – 1st Approved Targeted Alpha Therapy
8.1 Overview & Patent Insight
8.2 Pricing & Dosing


9. Targeted Alpha Therapy - Proprietary Technology Platform By Company


10. Global Targeted Alpha Therapy Market Dynamics
10.1 Drivers & Opportunities
10.2 Challenges & Restraints


11. Competitive Landscape
11.1 Actinium Pharma
11.2 AdvanCell
11.3 Bayer
11.4 Fusion Pharma
11.5 Johnson & Johnson
11.6 Modulation Therapeutics
11.7 Orano Med
11.8 Perspective Therapeutics
11.9 RayzeBio
11.10 Telix Pharmaceuticals



List of Figures

Figure 2-1: Targeted Alpha Therapy - Structure
Figure 2-2: Targeted Alpha Therapy - Mechanism Of Action

Figure 3-1: LIN-AC225-AML02 Phase 1/2 (NCT03867682) Study – Initiation & Completion Year
Figure 3-2: AcTRESS Phase 1 (NCT06411301) Study – Initiation & Completion Year
Figure 3-3: RG1121028 Phase 1 (NCT04579523) Study – Initiation & Completion Year
Figure 3-4: 225Ac-DOTA-daratumumab Phase 1 (NCT05363111) Study – Initiation & Completion Year
Figure 3-5: PAnTHA Phase 1 (NCT06217822) Study – Initiation & Completion Year
Figure 3-6: PSMA-617-100 Phase 1 (NCT04597411) Study – Initiation & Completion Year
Figure 3-7: BAY3546828 Phase 1 (NCT06052306) Study – Initiation & Completion Year
Figure 3-8: VMT-?-NET-T101 Phase 1/2a (NCT05636618) Study – Initiation & Completion Year
Figure 3-9: FPI-2059-101 Phase 1 (NCT05605522) Study – Initiation & Completion Year

Figure 4-1: Factors Influencing Future Market of Targeted Alpha Therapies
Figure 4-2: Global - Targeted Alpha Therapy Market Opportunity (US$ Million), 2025 & 2028

Figure 9-1: Fusion Pharma - Fast-Clear? Linker Technology
Figure 9-2: AdvanCell - Proprietary 212Pb Production Technology
Figure 9-3: Cellectar Biosciences - Phospholipid Ether (PLE) Platform Technology
Figure 9-4: Perspective Therapeutics – Proprietary Technology & Pb-212 Isotope
Generator VMT-?-NET

Figure 10-1: Global Targeted Alpha Therapy Market - Drivers & Opportunities
Figure 10-2: Global Targeted Alpha Therapy Market - Challenges & Restraints

List of Tables

Table 1 1: Alpha Radiation vs. Beta & Gamma Radiation In Cancer Therapy

Table 4-1: Efforts to Increase Radioisotope Production Capacity
Table 4-2: Recent Collaborations for Targeted Alpha Therapy Development

Table 6-1: Targeted Alpha Therapies In Research Stage, 2024
Table 6-2: Targeted Alpha Therapies In Preclinical Stage, 2024
Table 6-3: Targeted Alpha Therapies In Phase I, 2024
Table 6-4: Targeted Alpha Therapies In Phase I/II, 2024
Table 6-5: Targeted Alpha Therapies In Phase II, 2024
Table 6-6: Targeted Alpha Therapies In Phase II/III, 2024
Table 6-7: Targeted Alpha Therapies In Phase III, 2024

Table 7-1: Marketed Targeted Alpha Therapies, 2024
Table 8-1: Xofigo - Decay Correction Factor